ImmunoPrecise Antibodies Ltd. Files 20-F/A Amendment

TL;DR

IPA filed an amendment to its annual report for FY24, check for updates.

AI Summary

ImmunoPrecise Antibodies Ltd. filed an amendment (20-F/A) to its annual report for the fiscal year ended April 30, 2024. The filing, dated December 10, 2024, provides updated information regarding the company's operations and financial status. The company is incorporated in British Columbia and its principal executive offices are located in Victoria, Canada.

Why It Matters

This amendment to the annual report provides updated disclosures for investors and regulatory bodies, ensuring transparency regarding ImmunoPrecise Antibodies Ltd.'s financial and operational status.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, ImmunoPrecise Antibodies Ltd. is subject to regulatory risks, clinical trial outcomes, and market competition, which can impact its financial performance.

Key Numbers

• 001-39530 — SEC File Number (Identifies the company's filing with the SEC.)
• 20241210 — Filing Date (Date the amendment was submitted to the SEC.)

Key Players & Entities

• ImmunoPrecise Antibodies Ltd. (company) — Registrant
• Kristin Taylor (person) — Contact Person
• 001-39530 (dollar_amount) — SEC File Number
• April 30, 2024 (date) — Fiscal Year End
• December 10, 2024 (date) — Filing Date

FAQ

Filing Documents

• ipa-20241210.htm (20-F/A) — 67KB
• ipa-ex12_1.htm (EX-12.1) — 10KB
• ipa-ex12_2.htm (EX-12.2) — 10KB
• ipa-ex13_1.htm (EX-13.1) — 8KB
• ipa-ex13_2.htm (EX-13.2) — 8KB
• 0000950170-24-134775.txt ( ) — 103KB

Item 18

Item 17 Item 18 If this is an annual report, indicate by check mark whether the Company is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No EXPLANATORY NOTE ImmunoPrecise Antibodies Ltd. is filing this Amendment No. 1 to the Annual Report on Form 20-F for fiscal year ended April 30, 2024 (the “Form 20-F/A”), which was originally filed with the Securities and Exchange Commission on July 29, 2024 (the “Original Form 20-F”), solely to correct a typographical error relating to the wrong fiscal period presented under “Item 15. B. Management’s Annual Report on Internal Control Over Financial Reporting”. This Form 20-F/A does not reflect events occurring after the filing of the Original Form 20-F and does not modify or update the disclosure therein in any way except as described above. No other changes have been made to the Original Form 20-F. Accordingly, this Form 20-F/A should be read in conjunction with the Original Form 20-F. As required by Rule 12b-15 under the United States Securities Exchange Act of 1934, as amended, new certifications of our principal executive officer and principal financial officer are filed as exhibits to this Form 20-F/A under Item 19 hereof.

CONTROLS AND PROCEDURES

ITEM 15. CONTROLS AND PROCEDURES A. Disclosure Controls and Procedures Management of the Company, under the supervision of the Company’s CEO and CFO, is responsible for establishing and maintaining disclosure controls and procedures (as defined by the SEC in Rule 13a-15(e) and 15d-15(e) of the Exchange Act) for the Company to ensure that material information relating to the Company, including its consolidated subsidiaries, that is required to be made known to the CEO and CFO by others within the Company and disclosed by the Company in reports filed or submitted by it under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms; and (ii) accumulated and communicated to the Company’s management, including its CEO and CFO, to allow timely decisions regarding required disclosure. The CEO and the CFO, along with management, have evaluated and concluded that the Company’s disclosure controls and procedures as at April 30, 2024 were effective. B. Management’s Annual Report on Internal Control Over Financial Reporting The Company’s management has employed a framework consistent with Exchange Act Rule 13a-15(c), to evaluate the Company’s internal control over financial reporting described below. A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparatio

EXHIBITS

ITEM 19. EXHIBITS EXHIBIT INDEX Exhibit No. Item Description of Exhibit 12.1 Certification of the Chief Executive Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934 12.2 Certification of the Chief Financial Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934 13.1 Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 13.2 Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

SIGNATURES The Registrant hereby certifies that it meets all of the requirements for filing on Form 20-F/A and that it has duly caused and authorized the undersigned to sign this Annual Report on its behalf. IMMUNOPRECISE ANTIBODIES LTD. Date: December 10, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer

View Full Filing

View this 20-F/A filing on SEC EDGAR